[A Case of Gastric Cancer with Pulmonary Carcinomatous Lymphangitis and Disseminated Carcinomatosis of the Bone Marrow Responding to S-1 plus Cisplatin Chemotherapy]

Gan To Kagaku Ryoho. 2023 Dec;50(12):1319-1321.
[Article in Japanese]

Abstract

A 63-year-old man was admitted to a hospital owing to shortness of breath. He was diagnosed as having gastric cancer with pulmonary carcinomatous lymphangitis(PCL)and disseminated carcinomatosis of the bone marrow(DCBM). Regarding tumor markers, carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)levels increased to 332 ng/ mL and 921 U/mL, respectively. Since the disease was also accompanied by disseminated intravascular coagulation(DIC), S- 1 plus cisplatin chemotherapy was started immediately(S-1 120 mg/body administered for 21 days and cisplatin 60 mg/m2 administered on day 8, 35 days for a course). Approximately 2 weeks after the initiation of chemotherapy, the patient's respiratory symptoms improved, and he recovered from DIC. After 2 chemotherapy courses, tumor marker levels decreased (CEA 9.3 ng/mL and CA19-9 314 U/mL), and the patient continued to receive chemotherapy without the deterioration of his physical condition for 5 months. However, he experienced fatigue after 4 courses, because of the progression of gastric cancer. Although the regimen was changed to ramucirumab plus paclitaxel chemotherapy, the patient died 8 months after the initiation of chemotherapy. An accumulation of cases is needed to establish treatment strategies for gastric cancer with PCL and/or DCBM.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Bone Marrow
  • CA-19-9 Antigen
  • Carcinoembryonic Antigen
  • Carcinoma*
  • Cisplatin
  • Drug Combinations
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lymphangitis* / drug therapy
  • Lymphangitis* / etiology
  • Male
  • Middle Aged
  • Peritoneal Neoplasms*
  • Stomach Neoplasms* / complications
  • Stomach Neoplasms* / drug therapy

Substances

  • S-1 plus cisplatin
  • Cisplatin
  • Carcinoembryonic Antigen
  • CA-19-9 Antigen
  • Drug Combinations